Islet cell transplantation

Current Opinion in Organ Transplantation

Volumn 13, Issue 6, 2008, Pages 633-638

  Vaithilingam, Vijayaganapathy ^a   Sundaram, Gayathri ^a   Tuch, Bernard E ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Apoptosis; Imaging; Incretin; Islets; Vascularization

Indexed keywords

EXENDIN 4; PANCRELIPASE; COLLAGENASE; IMMUNOSUPPRESSIVE AGENT; LIBERASE; PEPTIDE; THERMOLYSIN; TISSUE SCAFFOLD; UNCLASSIFIED DRUG; VENOM;

APOPTOSIS; CELL ENCAPSULATION; CELL EXPANSION; CELL FUNCTION; CELL ISOLATION; DIABETES MELLITUS; DRUG EFFECT; HUMAN; IN VITRO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN DONOR; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; REVASCULARIZATION; REVIEW; ANGIOGENESIS; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DONOR; GRAFT REJECTION; GRAFT SURVIVAL; INSULIN DEPENDENT DIABETES MELLITUS; METHODOLOGY; PANCREAS ISLET; PATHOLOGY; PATHOPHYSIOLOGY; STAINING; TRANSPLANTATION; VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGENASES; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; STAINING AND LABELING; THERMOLYSIN; TISSUE DONORS; TISSUE SCAFFOLDS; VENOMS;

EID: 60849083583     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328317a48b     Document Type: Review

References (34)

1. CITR, Collaborative Islet Transplant Registry 2007 scientific summary. http: //spitfire.emmes.com/study/isl/reports/081007-CITR07ScientificSummary- final.pdf.
2. Kin T, Zhai X, Murdoch TB, et al. Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. Am J Transplant 2007; 7:1233-1241.
3. Jung HS, Choi S-H, Kim S-J, et al. A better yield of islet cell mass from living pancreatic donors compared with cadaveric donors. Clin Transplant 2007; 21:738-743.
4. Zhao M, Muiesan P, Amiel SA, et al. Human islets derived from donors after cardiac death are fully biofunctional. Am J Transplant 2007; 7:2318-2325.
5. Sweet IR, Gilbert M, Jensen R, et al. Glucose-stimulation of cytochrome C reduction and oxygen consumption as assessment of human islet quality. Transplantation 2005; 80:1003-1011.
6. Sweet IR, Gilbert M, Scott S, et al. Glucose-stimulated increment in oxygen consumption rate as a standardized test of human islet quality. Am J Transplant 2008; 8:183-192.
7. Papas KK, Colton CK, Nelson RA, et al. Human islet oxygen consumption rate and DNA measurements predict diabetes reversal in nude mice. Am J Transplant 2007; 7:707-713.
8. Armann B, Hanson MS, Hatch E, et al. Quantification of basal and stimulated ROS levels as predictors of islet potency and function. Am J Transplant 2007; 7:38-47.
9. Eich T, Eriksson O, Sundin A, et al. Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation 2007; 84:893-898.
10. Gustavson SM, Rajotte RV, Hunkeler D, et al. Islet auto-transplantation into an omental or splenic site results in a normal beta cell but abnormal alpha cell response to mild noninsulin-induced hypoglycemia. Am J Transplant 2005; 5:2368-2377.
11. Stagner JI, Rilo HL, White KK. The pancreas as an islet transplantation site. Confirmation in a syngeneic rodent and canine autotransplant model. J Pancreas 2007; 8:628-636.
12. Rafael E, Tibell A, Rydén M, et al. Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up. Am J Transplant 2008; 8:458-462.
13. Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007; 56:2008-2015.
14. Dufour JM, Rajotte RV, Zimmerman M, et al. Development of ectopic site for islet transplantation, using biodegradable scaffolds. Tissue Eng 2005; 11:1323-1331.
15. Blomeier H, Zhang X, Rives C, et al. Polymer scaffolds as synthetic microenvironments for extrahepatic islet transplantation. Transplantation 2006; 82:452-459.
16. Salvay DM, Rives CB, Zhang X, et al. Extracellular matrix protein-coated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation. Transplantation 2008; 85:1456-1464.
17. Noguchi H, Nakai Y, Ueda M, et al. Activation of c-Jun NH2-terminal kinase (JNK) pathway during islet transplantation and prevention of islet graft loss by intraportal injection of JNK inhibitor. Diabetologia 2007; 50:612-619.
18. Fornoni A, Pileggi A, Molano RD, et al. Inhibition of c-jun N terminal kinase (JNK) improves functional beta cell mass in human islets and leads to AKT and glycogen synthase kinase-3 (GSK-3) phosphorylation. Diabetologia 2008; 51:298-308.
19. Ferdaoussi M, Abdelli S, Yang JY, et al. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 2008; 57:1205-1215.
20. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007; 83:24-28.
21. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 2008; 8:1250-1261.
22. Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 2008; 86:36-45.
23. Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Eng J Med 2008; 356:2754-2755.
24. Biancone L, Crich SG, Cantaluppi V, et al. Magnetic resonance imaging of gadolinium-labelled pancreatic islets for experimental transplantation. NMR Biomed 2007; 20:40-48.
25. Toso C, Vallee JP, Morel P, et al. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticles labelling. Am J Transplant 2008; 8:701-706.
26. Barnett BP, Arepally A, Karmarkar PV, et al. Magnetic resonance-guided, realtime targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells. Nat Med 2007; 13:986-991.
27. Morini S, Brown ML, Cicalese L, et al. Revascularization and remodeling of pancreatic islets grafted underthe kidney capsule. J Anat 2007; 210:565-577.
28. Cheng Y, Liu Y-F, Zhang J-L, et al. Elevation of vascular endothelial growth factor production and its effect on revascularization and function of graft islets in diabetic rats. World J Gastroenterol 2007; 13:2862-2866.
29. Cross SE, Richards SK, Clark A, et al. Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs. Diabetologia 2007; 50:1423-1432.
30. Su D, Zhang N, He J, et al. Angiopoietin-1 production in islets improves islet engraftment and protects islets from cytokine-induced apoptosis. Diabetes 2007; 56:2274-2283.
31. Johansson U, Rasmusson I, Niclou SP, et al. Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revascularization. Diabetes 2008; 57:2393-2401.
32. Calafiore R, Basta G, Luca G, et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 2006; 29:137-138.
33. Wang T, Adcock J, Kühtreiber W, et al. Successful allotransplantation of encapsulated islets in pancreatectomized canines for diabetic management without the use of immunosuppression. Transplantation 2008; 85:331-337.
34. Russ HA, Bar Y, Ravassard P, Efrat S. In vitro proliferation of cells derived from adult human beta-cells revealed by cell-lineage tracing. Diabetes 2008; 57:1575-1583.